The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Open accessPublished version of a preprint
Abstract
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 1-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC 50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of these NAb responses appear to correlate with viral load, with higher responses reported in patients with more severe disease, and in older adults compared with younger adults26–29.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In agreement with previous reports3,6,9, there was a broad range of plasma neutralizing activity 3–14 weeks after the second vaccine dose that was similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spike is the target of SARS-CoV-2 neutralizing antibodies, and the receptor binding domain (RBD) of Spike is the target of >90% of neutralizing antibodies in COVID-19 cases (Brouwer et al., 2020; Piccoli et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Suthar et al., 2020), with some neutralizing antibodies instead targeting the N-terminal domain (NTD) (Liu et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although it is unclear how long protective effects last beyond the first few months after vaccination, some studies suggest that the elicited neutralizing activity is maintained for up to 8 months after the natural infection with SARS-CoV-2 (refs. 41,42).”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredIn the citing paper
“8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“In line with previous reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were similar (Extended Data Fig 1j–l).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“We limited our analysis to RBD because plasma RBD antibodies are strongly correlated with neutralizing activity3,10–12.”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Consistent with this observation, there was an overall increase in the apparent avidity of plasma antibodies between 1.3 and 12 months3,4 (P < 0.0001) (Extended Data Fig. 7c).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Most serum nAb responses elicited during natural infection are directed at the RBD (21, 23, 30, 31).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22–24, 32–37).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Analyses of the B cell responses to the spike generally focus on the RBD and on cells sorted with RBD baits introducing an inherent bias by omitting non-RBD targets”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“The neutralizing antibodies are produced by B cells with a wide range of heavy chain and light chain V genes (Robbiani et al., 2020; Rogers et al., 2020). SARS-CoV-2 neutralizing antibodies also exhibit little to no somatic hypermutation (Gaebler et al., 2020; Robbiani et al., 2020; Rogers et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“Although neutralizing antibody titers have not correlated with reduced COVID-19 severity (Dan et al., 2021; Piccoli et al., 2020; Robbiani et al., 2020), SARS-CoV-2 cTfh cell frequencies have been associated with reduced disease severity (Rydyznski Moderbacher et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“This appears to hold true in the case of SARS-CoV-2, where neutralizing antibody titers (and total Spike antibody titers) have positively correlated with COVID-19 disease severity in large cohort studies (Piccoli et al., 2020; Robbiani et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“However, it should also be noted that circulating SARS-CoV-2 neutralizing antibody titers are relatively low in a substantial fraction of recovered COVID-19 cases (Dan et al., 2021; Robbiani et al., 2020; Wajnberg et al., 2020), indicating that either the neutralizing antibody potency or the serum concentration is suboptimal in this subset.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,136
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T. M., Willey, R. L., Rabson, A. B., & Martín, M. Á. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,805
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Cited by
Sorted by citations
Items 601–700 of 1,017
Benschop, R. J., TUTTLE, J. L., Zhang, L., Poorbaugh, J., Kallewaard, N. L., Vaillancourt, P., Crisp, M., Trinh, T. N. V., Freitas, J. J., Beasley, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3041 · Cited by 38
Is Herd Immunity Against SARS-CoV-2 a Silver Lining?
Vignesh, R., Shankar, E. M., Velu, V., & Thyagarajan, S. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586781 · Cited by 37
Immune Response to SARS-CoV-2 Vaccines
Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 37
Immune Imprinting and Implications for COVID-19
Zhou, Z., Barrett, J., & He, X. (2023) · Vaccines · doi:10.3390/vaccines11040875 · Cited by 37
Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020
Gidding, H. F., Machalek, D. A., Hendry, A. J., Quinn, H., Vette, K., Beard, F., Shilling, H. S., Hirani, R., Gosbell, I. B., Irving, D. O., et al. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.50940 · Cited by 37
Yan, Q., He, P., Huang, X., Luo, K., Zhang, Y., Yi, H., Wang, Q., Li, F., Hou, R., Fan, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1925594 · Cited by 37
Mantus, G. E., Nyhoff, L. E., Edara, V. V., Zarnitsyna, V. I., Ciric, C. R., Flowers, M. W., Norwood, C., Ellis, M. L., Hussaini, L., Manning, K. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100603 · Cited by 37
Oliveira, A. S. F., Shoemark, D. K., Ibarra, A. Á., Davidson, A. D., Berger, I., Schaffitzel, C., & Mulholland, A. J. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.12.011 · Cited by 37
Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 37
Shi, W., Wang, L., Zhou, T., Sastry, M., Yang, E. S., Zhang, Y., Chen, M., Chen, X., Choe, M., Creanga, A., et al. (2022) · Structure · doi:10.1016/j.str.2022.06.004 · Cited by 37
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 37
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Cassaniti, I., Bergami, F., Percivalle, E., Gabanti, E., Sammartino, J. C., Ferrari, A., Adzasehoun, K. M. G., Zavaglio, F., Zelini, P., Comolli, G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.016 · Cited by 36
Luo, S., Jing, C., Ye, A. Y., Kratochvil, S., Cottrell, C. A., Koo, J., Chapdelaine-Williams, A. M., Francisco, L. V., Batra, H., Lamperti, E. D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217883120 · Cited by 36
Gaspar-Castillo, C., Rodriguez, M. H., Ortiz-Navarrete, V. F., Alpuche-Aranda, C. M., & Martínez-Barnetche, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1107496 · Cited by 36
Korenkov, M., Zehner, M., Cohen‐Dvashi, H., Borenstein-Katz, A., Kottege, L., Janicki, H., Vanshylla, K., Weber, T., Gruell, H., Koch, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.004 · Cited by 36
Germline immunoglobulin genes: Disease susceptibility genes hidden in plain sight?
Collins, A. M., Yaari, G., Shepherd, A. J., Lees, W., & Watson, C. T. (2020) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2020.10.011 · Cited by 36
Cardozo, T. J., & Veazey, R. S. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13795 · Cited by 36
Yang, Y., Shi, W., Abiona, O. M., Nazzari, A. F., Olia, A. S., Ou, L., Phung, E., Stephens, T., Tsybovsky, Y., Verardi, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9020073 · Cited by 36
Walker, G. J., Naing, Z., Stella, A. O., Yeang, M., Caguicla, J., Ramachandran, V., Isaacs, S. R., Agapiou, D., Bull, R. A., Stelzer‐Braid, S., et al. (2021) · Viruses · doi:10.3390/v13020247 · Cited by 36
Dopico, X. C., Muschiol, S., Christian, M., Hanke, L., Sheward, D. J., Grinberg, N. F., Rorbach, J., Bogdanović, G., McInerney, G. M., Allander, T., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13304 · Cited by 36
Bonanni, P., Cantón, R., Gill, D., Halfon, P., Liebert, U. G., Crespo, K. A. N., Martín, J. J. P., & Trombetta, C. M. (2021) · COVID · doi:10.3390/covid1010004 · Cited by 36
Current strategies for detecting functional convergence across B-cell receptor repertoires
Raybould, M. I. J., Rees, A. R., & Deane, C. M. (2021) · mAbs · doi:10.1080/19420862.2021.1996732 · Cited by 36
Rodrigues, K. A., Rodriguez‐Aponte, S. A., Dalvie, N. C., Lee, J. H., Abraham, W. D., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Chang, J. Y. H., Zhang, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj6538 · Cited by 36
Ferrara, F., Erasmus, M. F., D’Angelo, S., Leal‐Lopes, C., Teixeira, A. A. R., Choudhary, A. K., Honnen, W. J., Calianese, D. C., Huang, D., Peng, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27799-z · Cited by 36
Yan, L., Liu, P., Li, X.-G., Zhou, S.-J., Li, H., Wang, Z.-Y., Shen, F., Lu, B., Long, Y., Xiao, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.803031 · Cited by 36
Self-citationCOVID-19: imbalanced cell-mediated immune response drives to immunopathology
Wang, J., Li, Q., Qiu, Y., & Lu, H. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2122579 · Cited by 36
Zedan, H. T., Yassine, H. M., Al‐Sadeq, D. W., Liu, N., Qotba, H. A., Nicolai, E., Pieri, M., Bernardini, S., Abu-Raddad, L. J., & Nasrallah, G. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-21317-x · Cited by 36
Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., et al. (2021) · doi:10.1101/2021.05.07.21256823 · Cited by 240
Methods for sequence and structural analysis of B and T cell receptor repertoires
Teraguchi, S., Saputri, D. S., Llamas-Covarrubias, M. A., Davila, A., Díez, D., Nazlica, S. A., Rozewicki, J., Ismanto, H. S., Wilamowski, J., Xie, J., et al. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.07.008 · Cited by 35
Cloutier, M., Nandi, M., Ihsan, A. U., Allard‐Chamard, H., Ilangumaran, S., & Ramanathan, S. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155256 · Cited by 35
A review of COVID-19 biomarkers and drug targets: resources and tools
Caruso, F. P., Scala, G., Cerulo, L., & Ceccarelli, M. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa328 · Cited by 35
Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
Taefehshokr, N., Taefehshokr, S., & Heit, B. (2020) · Pathogens · doi:10.3390/pathogens9121027 · Cited by 35
Horndler, L., Delgado, P., Abia, D., Balabanov, I., Martínez‐Fleta, P., Cornish, G. H., Llamas, M. Á., Villar, S. S., Sánchez‐Madrid, F., Fresno, M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013549 · Cited by 35
Overcoming Immunological Challenges Limiting Capsid-Mediated Gene Therapy With Machine Learning
Wec, A. Z., Lin, K. S., Kwasnieski, J. C., Sinai, S., Gerold, J., & Kelsic, E. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674021 · Cited by 35
Volk, A., Covini-Souris, C., Kühnel, D., de Mey, C., Römisch, J., & Schmidt, T. (2021) · BioDrugs · doi:10.1007/s40259-021-00511-9 · Cited by 35
Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C., Buisson, M., Gallet, S., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.011 · Cited by 35
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Silwal, A. P., Thennakoon, S. K. S., Arya, S. P., Postema, R. M., Jahan, R., Phuoc, C. M. T., & Tan, X. (2022) · Theranostics · doi:10.7150/thno.74428 · Cited by 35
Tauzin, A., Nicolas, A., Ding, S., Benlarbi, M., Medjahed, H., Chatterjee, D., Dionne, K., Gong, S. Y., Gendron‐Lepage, G., Bo, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.111998 · Cited by 35
Yu, S., Lin, Y., Li, Y., Chen, S., Zhou, L., Song, H., Yang, C., Zhang, H., Zhou, J., Sun, S.-C., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.033 · Cited by 35
Self-citationRosati, M., Terpos, E., Ntanasis‐Stathopoulos, I., Agarwal, M., Bear, J., Burns, R. T., Hu, X., Korompoki, E., Donohue, D. E., Venzon, D. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793953 · Cited by 34
Maltseva, M., Keeshan, A., Cooper, C., & Langlois, M. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2384192 · Cited by 34
Emmenegger, M., Cecco, E. D., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D. V., Schneider, M. M., Morales, I. C., et al. (2023) · iScience · doi:10.1101/2020.05.31.20118554 · Cited by 34
Behrens, G. M. N., Cossmann, A., Stankov, M. V., Schulte, B., Streeck, H., Förster, R., Bošnjak, B., Willenzon, S., Boeck, A.-L., Tran, A. T., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00334-1 · Cited by 34
Omersel, J., & Kuželički, N. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113561 · Cited by 34
Piri, S. M., Edalatfar, M., Shool, S., Jalalian, M. N., & Tavakolpour, S. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1871066 · Cited by 34
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
Dehgani‐Mobaraki, P., Zaidi, A. K., Yadav, N., Floridi, A., & Floridi, E. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108814 · Cited by 34
Peptide-Based Vaccines and Therapeutics for COVID-19
Bagwe, P. V., Bagwe, P., Ponugoti, S. S., & Joshi, S. V. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-022-10397-y · Cited by 34
B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination
Prabhu, P. R., Carter, J. J., & Galloway, D. A. (2022) · Vaccines · doi:10.3390/vaccines10060837 · Cited by 34
Ortega, M. R., Spisak, N., Mora, T., & Walczak, A. M. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010652 · Cited by 34
Coronavirus vaccine trials have delivered their first results — but their promise is still unclear
Callaway, E. (2020) · Nature · doi:10.1038/d41586-020-01092-3 · Cited by 34
Lim, S. A., Gramespacher, J. A., Pance, K., Rettko, N. J., Solomon, P. E., Jin, J., Lui, I., Elledge, S. K., Liu, J., Bracken, C. J., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1893426 · Cited by 33
Aldea, M. D., Michot, J., Danlos, F., Ribas, A., & Soria, J. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0144 · Cited by 33
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 33
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 33
Advances in human monoclonal antibody therapy for HBV infection
Beretta, M., & Mouquet, H. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101205 · Cited by 33
Zhang, S., Xu, K., Li, C., Zhou, L., Kong, X., Peng, J., Zhu, F., Bao, C., Jin, H., Gao, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829665 · Cited by 33
Chen, W., Zhang, L., Li, J., Bai, S., Wang, Y., Zhang, B., Zheng, Q., Chen, M., Zhao, W., & Wu, J. (2022) · Immunology · doi:10.1111/imm.13531 · Cited by 33
Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus
Lee, J., Zepeda, S. K., Park, Y., Taylor, A. L., Quispe, J. D., Stewart, C., Leaf, E. M., Treichel, C., Corti, D., King, N. P., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.018 · Cited by 33
What do we know about the antibody responses to SARS-CoV-2?
Lagunas‐Rangel, F. A., & Chávez‐Valencia, V. (2021) · Immunobiology · doi:10.1016/j.imbio.2021.152054 · Cited by 32
Banjar, A., Al‐Tawfiq, J. A., Alruwaily, A., Alserehi, H., Alqunaibet, A., Alaswad, R., Almutlaq, H., Almudaiheem, A., Khojah, A. T., Alsaif, F. K., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.028 · Cited by 32
Longitudinal analysis of antibody decay in convalescent COVID-19 patients
Xia, W., Li, M., Wang, Y., Kazis, L. E., Berlo, K., Melikechi, N., & Chiklis, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-96171-4 · Cited by 32
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Abhyankar, M. M., Mann, B. J., Sturek, J. M., Brovero, S. G., Moreau, G. B., Sengar, A., Richardson, C. M., Agah, S., Pomés, A., Kasson, P. M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00399-0 · Cited by 32
Wang, Y.-D., Liu, M., Shen, Y., Ma, Y., Li, X., Zhang, Y., Liu, M., Yang, X., Chen, J., Yan, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00401-6 · Cited by 32
Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire
Melani, R. D., Soye, B. J. D., Kafader, J. O., Forte, E., Hollas, M. A. R., Blagojevic, V., Negrão, F., McGee, J. P., Drown, B., Lloyd-Jones, C., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00882 · Cited by 32
He, B., Liu, S., Xu, M., Hu, Y., Lv, K., Wang, Y., Ma, Y., Zhai, Y., Yue, X., Liu, L., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2105261 · Cited by 32
Self-citationLiu, H., Kaku, C. I., Song, G., Yuan, M., Andrabi, R., Burton, D. R., Walker, L. M., & Wilson, I. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03700-6 · Cited by 32
Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
Gruell, H., Vanshylla, K., Tober‐Lau, P., Hillus, D., Sander, L. E., Kurth, F., & Klein, F. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00580-1 · Cited by 32
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32
The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2
Allen, J. D., Ivory, D. P., Song, G., He, W., Capozzola, T., Yong, P., Burton, D. R., Andrabi, R., & Crispin, M. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112307 · Cited by 32
Röltgen, K., Wirz, O. F., Stevens, B., Powell, A. E., Hogan, C. A., Najeeb, J., Hunter, M., Sahoo, M. K., Huang, C., Yamamoto, F. F., et al. (2020) · medRxiv · doi:10.1101/2020.08.15.20175794 · Cited by 32
SARS -CoV-2 T-cell immunity to variants of concern following vaccinationPreprint
Gallagher, K., Leick, M. B., Larson, R. C., Berger, T. R., Katsis, K., Yam, J. Y., Brini, G., Grauwet, K., MGH COVID-19 Collection & Processing Team, & Maus, M. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442455 · Cited by 32
Ma, H., Zhao, D., Zeng, W., Yang, Y., Hu, X., Zhou, P., Weng, J., Cheng, L., Zheng, X., & Jin, T. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1805-0 · Cited by 31
Ghodake, G. S., Shinde, S. K., Kadam, A. A., Saratale, R. G., Saratale, G. D., Syed, A., Elgorban, A. M., Marraiki, N., & Kim, D.-Y. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.112969 · Cited by 31
Takeshita, M., Nishina, N., Moriyama, S., Takahashi, Y., Uwamino, Y., Nagata, M., Aoki, W., Masaki, K., Ishii, M., Saya, H., et al. (2021) · Virology · doi:10.1016/j.virol.2020.12.020 · Cited by 31
Zhou, X., Ma, F., Xie, J., Yuan, M., Li, Y., Shaabani, N., Zhao, F., Huang, D., Wu, N. C., Lee, C.-C. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109109 · Cited by 31
Chen, H.-Y., Huang, C., Tian, L., Huang, X., Zhang, C., Llewellyn, G. N., Rogers, G. L., Andresen, K., O’Gorman, M. R. G., Chen, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00966-21 · Cited by 31
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
Liang, Q., Wang, Y., Zhang, S., Sun, J., Sun, W., Li, J., Liu, Y., Li, M., Cheng, L., Jiang, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104043 · Cited by 31
Winklmeier, S., Eisenhut, K., Taskin, D., Rübsamen, H., Gerhards, R., Schneider, C., Wratil, P. R., Stern, M., Eichhorn, P., Keppler, O. T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103659 · Cited by 31
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J. B., Kramer, K. J., Armstrong, E., Myers, L., Trivette, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159062 · Cited by 31
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 31
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Greaney, A. J., Kim, C., Kim, S., Hanke, L., Hyllner, E., Dyrdak, R., Lee, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101577 · Cited by 31
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31
Rosati, M., Terpos, E., Homan, P., Bergamaschi, C., Karaliota, S., Ntanasis‐Stathopoulos, I., Devasundaram, S., Bear, J., Burns, R., Bagratuni, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292568 · Cited by 30
Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques
Wang, H., Cheng, C., Santo, J. L. D., Shen, C., Bylund, T., Henry, A. R., Howe, C. A., Hwang, J., Morano, N. C., Morris, D. J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.003 · Cited by 30
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
Ding, S., Laumaea, A., Benlarbi, M., Beaudoin-Bussières, G., Gasser, R., Medjahed, H., Pancera, M., Stamatatos, L., McGuire, A. T., Bazin, R., et al. (2020) · Viruses · doi:10.3390/v12111214 · Cited by 30
Sasisekharan, V., Pentakota, N., Jayaraman, A., Tharakaraman, K., Wogan, G. N., & Narayanasami, U. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021615118 · Cited by 30
McGill, A. R., Khalil, R., Dutta, R., Green, R. J., Howell, M., Mohapatra, S., & Mohapatra, S. S. (2021) · Infectious Disease Reports · doi:10.3390/idr13010013 · Cited by 30
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Kurup, D., Malherbe, D. C., Wirblich, C., Lambert, R., Ronk, A. J., Diba, L. Z., Bukreyev, A. A., & Schnell, M. J. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009383 · Cited by 30
Chen, J., Wang, B., Caserto, J. S., Shariati, K., Cao, P., Pan, Y., Xu, Q., & Ma, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101714 · Cited by 30
Clinical progress in MSC-based therapies for the management of severe COVID-19
Rossello-Gelabert, M., Gonzalez‐Pujana, A., Igartúa, M., Santos‐Vizcaíno, E., & Hernández, R. M. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.002 · Cited by 30
Effect of D614G Spike Variant on Immunoglobulin G, M, or A Spike Seroassay Performance
Klumpp-Thomas, C. A., Kalish, H. R., Hicks, J. A., Mehalko, J. L., Drew, M. R., Memoli, M. J., Hall, M. D., Esposito, D., & Sadtler, K. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa743 · Cited by 29
Structural Immunology of SARS ‐ CoV ‐2
Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29
Haun, B. K., Lai, C.-Y., Williams, C. A., Wong, T. A. S., Lieberman, M. M., Pessaint, L., Andersen, H., & Lehrer, A. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599587 · Cited by 29
High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2
Vanhove, B., Duvaux-Miret, O., Rousse, J., Royer, P., Evanno, G., Ciron, C., Lhériteau, E., Vacher, L., Gervois, N., Oger, R., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202049072 · Cited by 29
One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses
Haddad, N. S., Nguyen, D. C., Kuruvilla, M. E., Morrison-Porter, A., Anam, F. A., Cashman, K. S., Ramonell, R. P., Kyu, S. Y., Saini, A. S., Cabrera-Mora, M., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100011 · Cited by 29
Self-citationGoenka, A., Halliday, A., Gregorová, M., Milodowski, E., Thomas, A. C., Williamson, M. K., Baum, H. E., Oliver, E., Long, A. E., Knežević, L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100327 · Cited by 29
Metadata
- Authors
- Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hägglöf, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., Bianchini, F., Chen, S. T., Ramos, V., Patel, R., Dizon, J., Shimeliovich, I., Mendoza, P., Hartweger, H., Nogueira, L., Pack, M., Horowitz, J., Schmidt, F., Weisblum, Y., Michailidis, E., Ashbrook, A. W., Waltari, E., Pak, J. E., Huey-Tubman, K. E., Koranda, N., Hoffman, P. R., West, A. P., Rice, C. M., Hatziioannou, T., Bjorkman, P. J., Bieniasz, P. D., Caskey, M., & Nussenzweig, M. C.
- Affiliations
- Institute for Research in Biomedicine (CH)
- Rockefeller University (US)
- California Institute of Technology (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Robbiani, Davide F.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- ORCID
- Robbiani, Davide F.
- Gaebler, Christian
- Muecksch, Frauke
- Lorenzi, Julio C. C.
- Wang, Zijun
- Cho, Alice
- Agudelo, Marianna
- Barnes, Christopher O.
- Gazumyan, Anna
- Finkin, Shlomo
- Hägglöf, Thomas
- Oliveira, Thiago Y.
- Viant, Charlotte
- Hurley, Arlene
- Hoffmann, Hans-Heinrich
- Millard, Katrina G.
- Kost, Rhonda G.
- Cipolla, Melissa
- Bianchini, Filippo
- Chen, Spencer T.
- Dizon, Juan
- Shimeliovich, Irina
- Mendoza, Pilar
- Hartweger, Harald
- Nogueira, Lilian
- Schmidt, Fabian
- Weisblum, Yiska
- Michailidis, Eleftherios
- Ashbrook, Alison W.
- Waltari, Eric
- Pak, John E.
- Koranda, Nicholas
- Hoffman, Pauline R.
- West, Anthony P.
- Rice, Charles M.
- Bjorkman, Pamela J.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- Venue
- Nature
- Published
- 2020-06-18
- Volume
- 584
- Issue
- 7821
- Pages
- 437-442
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7442695
- OpenAlex
- W3036386821
- Cited by
- 1,853
- References
- 47
- Citations by year
- 2026: 49 · 2025: 79 · 2024: 115 · 2023: 194 · 2022: 403 · 2021: 691 · 2020: 321
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute (UL1TR001866)
- George Mason University
- California Institute of Technology
- Fast Grants
- National Institutes of Health (P01-AI138398-S1, AI150464, TR001866, UL1TR001866)
- Beckman Institute, California Institute of Technology
- National Institute of Allergy and Infectious Diseases (R01AI091707, R01AI078788, P50AI150464, U19AI111825, P01AI138938, R37AI064003, T32AI070084)
- National Center for Advancing Translational Sciences (TR001866)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, convalescent plasma, neutralizing antibodies, receptor binding domain, spike protein, antibody response, memory B cells, pseudovirus neutralization, vaccine design, antibody epitopes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
